Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Nektar Therapeutics (NKTR) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Nektar Therapeutics (NKTR) - free report >>
Image: Bigstock
Sarepta (SRPT) Posts Y/Y Wider Q2 Loss, Eteplirsen in Focus
Sarepta Therapeutics, Inc. (SRPT - Free Report) reported a loss of $1.34 per share in the second quarter of 2016, wider than both the Zacks Consensus Estimate of a loss of $1.19 and the year-ago loss of $1.01.
The company did not record any revenue in the reported quarter, as was the case a year ago. The Zacks Consensus Estimate for revenues was $1.10 million.
Other Details
Research and development expenses increased 51.7% year over year to $44.3 million, while general and administrative expenses were up almost 38% to $17.8 million.
SAREPTA THERAP Price, Consensus and EPS Surprise
SAREPTA THERAP Price, Consensus and EPS Surprise | SAREPTA THERAP Quote
Sarepta’s lead candidate, eteplirsen, is currently under review in the U.S. The company is looking to get eteplirsen approved for the treatment of patients suffering from Duchenne muscular dystrophy amenable to exon 51 skipping.
We remind investors that the FDA had failed to provide a decision on the candidate by the extended Prescription Drug User Fee Act (PDUFA) date of May 26, 2016 (previous deadline: Feb 26, 2016). The agency informed the company that it was still reviewing the New Drug Application (NDA) and will try to reach a decision as early as possible.
This June, the FDA requested the company to provide dystrophin data from biopsies obtained from the ongoing confirmatory study on eteplirsen as part of the agency’s ongoing evaluation of the NDA.
Given that Sarepta has no approved product in its portfolio at the moment and that eteplirsen is its lead pipeline candidate, the delay in its approval is weighing on the company’s prospects. Investor focus is expected to remain on the approval status of eteplirsen.
Sarepta is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include Nektar Therapeutics (NKTR - Free Report) , CytRx Corporation and Innoviva, Inc. (INVA - Free Report) . Each of these stock sports a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>